Key result
High throughput screening of approximately 6800 small molecules identified several novel inhibitors of SARS-CoV 3CL(pro) with IC50 in the low micromolar range, including one that also inhibited PV 3C(pro).
Identified novel small molecule inhibitors targeting both coronavirus and picornavirus main proteases, providing structural insights for antiviral development.
Answers are grounded in this paper and cite their sources.
May inform dual protease inhibitor design; leaves open in vivo efficacy and clinical translation.
Picornaviruses (PV) and coronaviruses (CoV) are positive-stranded RNA viruses which infect millions of people worldwide each year, resulting in a wide range of clinical outcomes. As reported in this study, using high throughput screening against approximately 6800 small molecules, we have identified several novel inhibitors of SARS-CoV 3CL(pro) with IC(50) of low microM. Interestingly, one of them equally inhibited both 3C(pro) and 3CL(pro) from PV and CoV, respectively. Using computer modeling, the structural features of these compounds as individual and common protease inhibitors were elucidated to enhance our knowledge for developing anti-viral agents against PV and CoV.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2009) studied Picornavirus and coronavirus infections. Small molecule inhibitors was evaluated on Inhibition of SARS-CoV 3CL(pro) and PV 3C(pro) (IC50 of low microM). High throughput screening of approximately 6800 small molecules identified several novel inhibitors of SARS-CoV 3CL(pro) with IC50 in the low micromolar range, including one that also inhibited PV 3C(pro).
Synapse has enriched 10 related papers. Consider them for comparative context: